The Center for Vaccine Research is an integral part of Statens Serum Institut (SSI), which is under the auspices of the Danish Ministry of Health, with the main duty to ensure preparedness against infectious diseases and biological threats as well as control of congenital disorders.
SSI is responsible for Denmark’s preparedness against and control of infectious diseases, involving disease surveillance through international collaborations, as well as consultation with the Danish healthcare system and authorities in the event of epidemics that demand urgent action.
Research is an integral part of SSI’s infectious diseases control and preparedness strategy and, among many other subjects, encompasses world-class basic vaccine research that focuses on immunologic responses to infection, as well as basic and translational vaccine research.
SSI’s vaccine research, which is placed under the control of the Center for Vaccine Research, covers the whole span from hypothesis generation and basic research to vaccines in clinical use. The vaccine research programme is also an integral part of SSI’s core mission with respect to vaccine preparedness and supply.
The Center for Vaccine Research (CVR) consists of the Department of Infectious Immunology, Vaccine Development and QA/QC. The CVR includes a basic and translational research department and GMP facilities, as well as animal testing facilities employing expertise that enables the accelerated development of new vaccines targeted at regional infection threats.
The research in CVR has been focused on the identification and characterisation of antigens, immune mechanisms, vaccine delivery systems and immunostimulators that mediate protection against important pathogens such as Mycobacterium tuberculosis, Chlamydia trachomatis, Streptococcus pyogenes and Influenza.
The programme in CVR currently has two TB vaccines in late stage clinical testing and different liposomal adjuvant formulations, as well as a novel Chlamydia trachomatis vaccine in phase 1 trials.
The programme also has a number of advanced novel and innovative vaccine modalities in late stage preclinical evaluation. In collaboration with industrial partners, researchers at CVR have developed novel TB diagnostic tests (the IGRA assays) that are in widespread worldwide clinical use today.
They have also recently completed a large-scale phase 3 testing of a novel specific skin test reagent to substitute for tuberculin.